Atorvastatin decreases c-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-κb pathway

Cardiovascular Therapeutics

Volumn 28, Issue 1, 2010, Pages 8-14

  Li, Jie ^a   Li, Jian Jun ^a   He, Jian Guo ^a   Nan, Jing Long ^a   Guo, Yuan Lin ^a   Xiong, Chang Ming ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Atorvastatin; C reactive protein; Inflammation; Nuclear factor B; Pulmonary arterial hypertension

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; ATTENUATION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; INCUBATION TIME; INFLAMMATION; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY VASCULAR DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER;

ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CELLS, CULTURED; CHEMOKINE CCL2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PULMONARY ARTERY; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 74549116386     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00103.x     Document Type: Article

References (32)

1. Itoh T, Nagaya N, Ishibashi-Ueda H, et al. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 2006 11 : 158 163.
2. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995 151 : 1628 1631.
3. Humbert M, Monti G, Fartoukh M, et al. Platelet derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998 11 : 554 559.
4. Katsushi H, Kazufumi N, Hideki F, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J 2004 68 : 227 231.
5. Elstein D, Nir A, Klutstein M, Rudensky B, Zimran A. C-reactive protein and NT-proBNP as surrogate markers for pulmonary hypertension in Gaucher disease. Blood Cells Mol Dis 2005 34 : 201 205.
6. Kimura H, Okada O, Tanabe N, et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2001 164 : 319 324.
7. Kubo K, Hanaoka M, Hayano T, et al. Inflammatory cytokines in BAL fluid and pulmonary hemodynamics in high-altitude pulmonary edema. Respir Physiol 1998 111 : 301 310.
8. Kasahara Y, Kimura H, Kurosu K, Sugito K, Mukaida N, Matsushima K, Kuriyama T. MCAF/MCP-1 protein expression in a rat model for pulmonary hypertension induced by monocrotaline. Chest 1998 114 (Suppl 1 67S.
9. Bhargava A, Kumar A, Yuan N, Gewitz MH, Mathew R. Monocrotaline induces interleukin-6 mRNA expression in rat lungs. Heart Dis 1999 1 : 26 132.
10. Perkett EA, Pelton RW, Meyrick B, Gold LI, Miller DA. Expression of transforming growth factor-beta mRNAs and proteins in pulmonary vascular remodeling in the sheep air embolization model of pulmonary hypertension. Am J Respir Cell Mol Biol 1994 11 : 16 24.
11. Ikeda Y, Yonemitsu Y, Kataoka C, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2002 283 : H2021 H2028.
12. Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008 38 : 41 54.
13. Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006 130 : 326 333.
14. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002 106 : 913 919.
15. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003 58 : 186 195.
16. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerotic drugs. Circulation 2001 103 : 2531 2534.
17. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000 102 : 2165 2168.
18. Sawada H, Mitani Y, Maruyama J, et al. A nuclear factor-kappa B inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 2007 132 : 1265 1274.
19. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002 166 : 1403 1408.
20. Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, Johns RA. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003 285 : H938 H945.
21. Zhao L, Zhou TF, Liu HM, Li M, Dou H, Tang ZH. Effect of simvastatin on rat pulmonary hypertension induced by high pulmonary blood flow and injected monocrotaline. Sichuan Da Xue Xue Bao Yi Xue Ban 2007 38 : 463 465.
22. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003 108 : 1640 1645.
23. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006 291 : L668 L676.
24. Girgis RE, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007 292 : L1105 L1110.
25. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005 127 : 1446 1452.
26. Li J-J, Chen X-J. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis 2003 14 : 329 334.
27. Li J-J, Fang C-H, Qian H-Y, Hu W-L. Time course of rapid C-reactive protein reduction by pravastatin in patients with stable angina. Angiology 2006 57 : 1 7.
28. Sanchez O, Marcos E, Perros F, et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007 176 : 1041 1047.
29. Li J-J, Fang C-H. Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina. Clin Chem 2005 51 : 1735 1738.
30. Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and over-expression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 2006 373 : 401 414.
31. Carlin CM, Peacock AJ, Welsh DJ. Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. Am J Respir Cell Mol Biol 2007 37 : 447 456.
32. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005 172 : 987 993.